(Total Views: 474)
Posted On: 07/01/2021 9:53:50 PM
Post# of 148903
I’m voting a big No Way to this proposed group.
Cytodyn’s current team is getting the job done and meeting deadlines. Why change anything now? That is illogical and too much risk. See today’s press release. (BLA and NASH enrollment deadlines met!)
I’m very skeptical of the 5% group claim that they have been ignored (which of the 5%ers?).
Their letter states: “Yet they have continually refused to accept advice from highly qualified professionals”
In fact, current management does listen to highly qualified professionals. Look at the current Scientific Advisory Board – more credentialed than the proposed group:
This is Cytodyn’s SAB: Dr. Richard Maziarz, Dr. Mazen Noureddin, Dr. Norman Gaylis, Dr. Gero Hütter, Dr. Hope Rugo, Dr. Lishomwa (Lish) Ndhlovu, Dr. Eric Mininberg, Dr. Jonah Sacha
Just go to Cytodyn’s website and read about their credentials. They all agreed to be a part of Cytodyn, and respected current management enough to add their names and reputations, and advise the company.
(Also, I don’t understand the criticism of Scott Kelly – he has done a great job since he has been CMO and Head of Business Development since only April 2020. I’ve been an investor over 5 years and I think more progress has been made since, than ever before. It was all during a pandemic year too.)
I still have a fundamental problem with the 5% group that when 2 of its main backers had the opportunity to help lead Cytodyn, the share price didn’t do jack.
We all want to maximize our investment, however now is totally not the time to make such a drastic change.
This company is set up perfectly for a major inflection point this next 6 months with BLA, Brazil Covid, and possible Big Pharma license with Covid. (I have to admit, 5% group’s timing is awfully suspicious).
However, for whatever reason, if one year from now the sp is still around $2 and no approval, I might change my tune.
This next 6 months are crucial to the company, and I continue to support current management. I believe the current management is the right team.
Cytodyn’s current team is getting the job done and meeting deadlines. Why change anything now? That is illogical and too much risk. See today’s press release. (BLA and NASH enrollment deadlines met!)
I’m very skeptical of the 5% group claim that they have been ignored (which of the 5%ers?).
Their letter states: “Yet they have continually refused to accept advice from highly qualified professionals”
In fact, current management does listen to highly qualified professionals. Look at the current Scientific Advisory Board – more credentialed than the proposed group:
This is Cytodyn’s SAB: Dr. Richard Maziarz, Dr. Mazen Noureddin, Dr. Norman Gaylis, Dr. Gero Hütter, Dr. Hope Rugo, Dr. Lishomwa (Lish) Ndhlovu, Dr. Eric Mininberg, Dr. Jonah Sacha
Just go to Cytodyn’s website and read about their credentials. They all agreed to be a part of Cytodyn, and respected current management enough to add their names and reputations, and advise the company.
(Also, I don’t understand the criticism of Scott Kelly – he has done a great job since he has been CMO and Head of Business Development since only April 2020. I’ve been an investor over 5 years and I think more progress has been made since, than ever before. It was all during a pandemic year too.)
I still have a fundamental problem with the 5% group that when 2 of its main backers had the opportunity to help lead Cytodyn, the share price didn’t do jack.
We all want to maximize our investment, however now is totally not the time to make such a drastic change.
This company is set up perfectly for a major inflection point this next 6 months with BLA, Brazil Covid, and possible Big Pharma license with Covid. (I have to admit, 5% group’s timing is awfully suspicious).
However, for whatever reason, if one year from now the sp is still around $2 and no approval, I might change my tune.
This next 6 months are crucial to the company, and I continue to support current management. I believe the current management is the right team.
(15)
(0)Scroll down for more posts ▼
